Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2014', provides an overview of the Thrombocythaemia Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thrombocythaemia Myelofibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thrombocythaemia Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thrombocythaemia Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thrombocythaemia Myelofibrosis Overview 6
Therapeutics Development 7
Pipeline Products for Thrombocythaemia Myelofibrosis - Overview 7
Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis 8
Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies 9
Thrombocythaemia Myelofibrosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Thrombocythaemia Myelofibrosis - Products under Development by Companies 12
Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development 13
Gilead Sciences, Inc. 13
Incyte Corporation 14
MEI Pharma, Inc. 15
Nippon Shinyaku Co., Ltd. 16
Novartis AG 17
Thrombocythaemia Myelofibrosis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
buparlisib hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INCB-39110 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
luminespib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
momelotinib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NS-018 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
panobinostat - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pracinostat - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
simtuzumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Thrombocythaemia Myelofibrosis - Recent Pipeline Updates 50
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2014 7
Number of Products under Development for Thrombocythaemia Myelofibrosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Thrombocythaemia Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 13
Thrombocythaemia Myelofibrosis - Pipeline by Incyte Corporation, H2 2014 14
Thrombocythaemia Myelofibrosis - Pipeline by MEI Pharma, Inc., H2 2014 15
Thrombocythaemia Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 16
Thrombocythaemia Myelofibrosis - Pipeline by Novartis AG, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Thrombocythaemia Myelofibrosis Therapeutics - Recent Pipeline Updates, H2 2014 50